NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

DNX-2401(Tasadenoturev):對新興藥物的考慮和市場預測(2030)

DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959697
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
DNX-2401(Tasadenoturev):對新興藥物的考慮和市場預測(2030) DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

DNX-2401是一種溶解腫瘤的腺病毒,專門設計用於感染,複製和殺死癌細胞以引發免疫反應。先前的臨床試驗表明,DNX-2401具有良好的耐受性,可延長復發性膠質母細胞瘤患者的生存期。

DNX-2401已被EMA(歐洲藥品管理局)指定為PRIME(優先藥物)和罕見病藥物,並被美國食品藥品管理局(FDA)指定為快速通道(優先批准審查系統)和罕見病。給出了使用藥物的名稱。

在此報告中,詳細介紹了美國7個主要市場,5個歐洲國家(德國,法國,意大利,西班牙,英國)和日本的DNX-2401(Tasadenoturev)的詳細信息(產品詳細信息,作用機理,劑量) ,合成途徑,藥理研究,監管里程碑,其他開發活動等)。

目錄

第1章藥物概述

  • 產品詳細信息
  • 作用機理
  • 藥物和管理
  • 研發活動
    • 臨床發展
    • 安全性和有效性
  • 其他發展活動

第2章市場評估

  • 7個主要國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 意大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章SWOT分析

第4章分析師的觀點

第5章市場競爭者

第6章其他新療法

第7章附錄

第8章報表購買選項

目錄
Product Code: DIDM0048

"DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Glioblastoma in 7 Major Markets. A detailed picture of the DNX-2401 (TASADENOTUREV) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

DNX-2401 is an oncolytic adenovirus engineered specifically to infect, replicate in, and kill cancer cells to elicit an immune response. Prior clinical studies have demonstrated that DNX-2401 was well tolerated and extended survival for patients with recurrent glioblastoma. DNX-2401 is currently being evaluated in several clinical trials, including a multicenter Phase 2 study evaluating DNX-2401 with pembrolizumab for adult patients with recurrent glioblastoma. DNX-2401 has been granted PRIME and Orphan designation by the EMA, and Fast Track and Orphan designation by the FDA.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around DNX-2401 (Tasadenoturev).
  • The report contains forecasted sales for DNX-2401 (Tasadenoturev) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Glioblastoma.
  • The report also features the SWOT analysis with analyst insights and key findings of DNX-2401 (Tasadenoturev).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DNX-2401 (Tasadenoturev) Analytical Perspective by DelveInsight

  • In-depth DNX-2401 (Tasadenoturev) Market Assessment

This report provides a detailed market assessment of DNX-2401 (Tasadenoturev) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • DNX-2401 (Tasadenoturev) Clinical Assessment

The report provides the clinical trials information of DNX-2401 (Tasadenoturev) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Glioblastoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence DNX-2401 (Tasadenoturev) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Glioblastoma are giving market competition to DNX-2401 (Tasadenoturev) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of DNX-2401 (Tasadenoturev).
  • Our in-depth analysis of the forecasted sales data of DNX-2401 (Tasadenoturev) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DNX-2401 (Tasadenoturev).

Key Questions:

  • Which company is developing DNX-2401 (Tasadenoturev) along with the phase of the clinical study?
  • What is the technology utilized in the development of DNX-2401 (Tasadenoturev)?
  • What is the product type, route of administration and mechanism of action of DNX-2401 (Tasadenoturev)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DNX-2401 (Tasadenoturev) development?
  • What are the key designations that have been granted to DNX-2401 (Tasadenoturev)?
  • What is the forecasted market scenario of DNX-2401 (Tasadenoturev)?
  • What is the history of DNX-2401 (Tasadenoturev) and what is its future?
  • What is the forecasted sales of DNX-2401 (Tasadenoturev) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to DNX-2401 (Tasadenoturev)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 DNX-2401 (TASADENOTUREV), Description
  • Table 2 DNX-2401 (TASADENOTUREV), Clinical Trial Description
  • Table 3 DNX-2401 (TASADENOTUREV), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of DNX-2401 (TASADENOTUREV)
  • Figure 2 Patent Details, DNX-2401 (TASADENOTUREV)
  • Figure 3 DNX-2401 (TASADENOTUREV), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 DNX-2401 (TASADENOTUREV), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 DNX-2401 (TASADENOTUREV), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 DNX-2401 (TASADENOTUREV), Japan Market Size from 2020 to 2030 (in Millions USD)